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ABSTRACT
Alternative splicing is a significant contributor to
transcriptome diversity, and a high-throughput
experimental method to quantitatively assess predic-
tions from expressed sequence tag and microarray
analyses may help to answer questions about the
extent and functional significance of these variants.
Here, we describe a method for high-throughput
analysis of known or suspected alternative splicing
variants (ASVs) using PCR, primer extension
and matrix-assisted laser desorption ionization
time-of-flight mass spectrometry (MALDI-TOF MS).
Reverse-transcribed mRNA is PCR amplified with
primers surrounding the site of alternative splicing,
followed by a primer extension reaction designed to
targetsequencedisparitiesbetweentwoormorevari-
ants. These primer extension products are assayed
on a MALDI-TOF mass spectrometer and analyzed
automatically. This method is high-throughput,
highly accurate and reproducible, allowing for the
verification of the existence of splicing variants in a
variety of samples. An example given also demon-
strates how this method can eliminate potential
pitfalls from ordinary gel electrophoretic analysis of
splicing variants where heteroduplexes formed
from different variants can produce erroneous res-
ults.Thenewmethodcanbeusedtocreatealternative
variant profiles for cancer markers, to study complex
splicing regulation, or to screen potential splicing
therapies.
INTRODUCTION
Since the discovery of alternative splicing in 1977 (1), our
estimate of the degree to which pre-mRNA undergoes altern-
ative splicing increases every year as more studies are con-
ducted. In 1994, alternative splicing was thought to affect a
mere 5%ofgenes ineukaryotes(2), ﬁveyears later the number
jumped to 35% (3), and now, 28 years after its discovery some
researchers using microarrays have estimated that 74% of
human multi-exon genes are alternatively spliced (4) with
80% of these alternative splicing events producing changes
in protein sequences (5). Regardless of the ﬁnal tally, the
importance of alternative splicing is assured; for every role
of alternative splicing that we know of, there are many
more being uncovered. Examples of the functions of altern-
ative splicing include calcium pump diversity (6) and regula-
tion of ﬁbronectin (7), calcitonin (8) and GTP cyclohydrolase
I (9). In addition to its intended role in complex regulation of
signaling and expression, alternative splicing has been linked
to many well-characterized diseases, including cystic ﬁbrosis,
Alzheimer disease (10), Parkinson’s and Frasier syndrome
(11) as well as every major cancer (12). How these variants
are regulated through cis-regulatory elements and trans-acting
factors and how this knowledge can be used in diagnosis,
prognosis and treatment of the aforementioned diseases is an
active ﬁeld of study. With such vast and signiﬁcant roles
linked to alternative splicing, the need to fully characterize
alternative splicing qualitatively and quantitatively is
imperative.
To understand the impact of alternative splicing on the
complexity of the human genome, researchers have used
expressed sequence tag (EST) analysis and microarray proﬁl-
ing to determine possible variants that are tissue-speciﬁc,
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doi:10.1093/nar/gni098tumor-speciﬁc and disease-associated (12–16). These searches
have identiﬁed thousands of potential tissue-speciﬁc variants
and cancer-speciﬁc markers. Unfortunately, current methods
for verifying and quantifying these variants at the level needed
are either too low throughput or not sufﬁcient in quantitative
accuracy. Among many technologies that have been used for
alternative splicing analysis, polymerase colony technology
(17) was shown to be a particularly powerful method to
analyze extremely complex alternatively spliced genes, such
as CD44 or MAPT. However, it is unclear how the polony
technology can be adapted to clinical situations where high-
throughput analysis of hundreds of potential targets, scores of
tissue types and hundreds to thousands of samples are needed
to generate statistical signiﬁcance without being labor intens-
ive and cost prohibitive.
Here, we demonstrate one approach for alternative splicing
variant (ASV) quantiﬁcation. Complementary DNA (cDNA)
reverse transcribed from total RNA preparation is PCR amp-
liﬁed using primers that ﬂank the site of alternative splicing.
To distinguishdifferent ASVs,anextension primerisdesigned
to extend from one toa few bases into the sequencedifferences
introduced by alternative splicing, such that the different
variants create products of different molecular weights.
Matrix-assisted laser desorption ionization time-of-ﬂight
mass spectrometry (MALDI-TOF MS) is then used to detect
andquantifytheseproducts.Theentireprocessiscarriedoutin
a 384-well plate format in a highly automated fashion so that a
single person can carry out a few thousand reactions per day.
MATERIALS AND METHODS
Samples and reverse transcription
Total RNA samples from six healthy human tissue samples,
including brain, colon, heart, kidney, liver and testis, were
obtained from Clontech. A sample of 100 ng of RNA was
reverse transcribed for 1 h at 42 C with 0.5 mg of random
hexanucleotides and an AMV reverse transcriptase (Promega)
in 20 ml total volume.
PCR primer design, amplification and primer extension
Primers were designed using Sequenom’s Assay Designer
software (Table 1) and obtained from Integrated DNA Tech-
nology (Coralville, IA). PCR primers were tagged with 50-
ACGTTGGATG-30 at the 50 end to avoid interference with
the mass spectra (tag sequence is not shown in Table 1).
Ampliﬁcation of 10 ng of cDNA was performed using PCR
primers at 100 nM, MgCl2 at 2.75 mM and 200 mM dNTP
using 0.1 U HotStart Taq DNA polymerase (Qiagen) in 5 ml
with the following PCR conditions: 95 C hot start for 15 min,
followed by 45 cycles of 95 C for 30 s, 56 C for 1 min, then
72 C for 1:30 min, with a ﬁnal hold of 72 C of 7 min. After the
PCR ampliﬁcation, the products were treated with 0.04 U
shrimp alkaline phosphatase, SAP (Sequenom), which inac-
tivatesunuseddNTPsfromtheampliﬁcationcycles,for20min
at 37 C followed by heat inactivation at 85 C for 5 min. For
the extension cycle, 1.2 mM ﬁnal concentration of extension
primer and 0.6 U of ThermoSequenase (Sequenom) were
added to a total reaction of 9 ml with the termination mixture
containing speciﬁc dideoxynucleotides and deoxynucleotides
for each reaction at 50 mM for each base. The extension
conditions include a 94 C hold for 2 min with 75 cycles of
the following: 94 C for 5 s, 52 C for 5 s and 72 C for 5 s.
MALDI-TOF MS and quantitative analysis
Prior to MALDI-TOF MS analysis, salts from the reactions
were removed using SpectroCLEAN resin and 16 ml of water.
ASV analysis was performed using the MassARRAY system
(Sequenom) by dispensing  10 nl of ﬁnal product onto
a 384-plate format MALDI-TOF MS SpectroCHIP using a
SpectroPOINT nanodispenser (Sequenom). The frequency of
each variant was generated by SpectroTYPER (Sequenom)
and was determined by taking the peak area ratio of the
peak associated with the splice variant of interest over the
Table 1. Primer and termination mixes for ASV analysis
Gene
a PCR primer 1 PCR primer 2 Extension primer Termination
mixture
b
HNRPA2B1, NM_031243 AGATTCTCTCTCATCTCGCTC TCCCTCATTACCACACAGTC GAACTGTTCCTTTTCTCTCT CG
ACTN-4, NM_004924 ACAGACCAGAGCTGATTGAG CTGTCAACCAAGAGAACGAGCA ATGCTGGATGCAGAGGA ACG
BCL2L1, NM_001191 ATCAATGGCAACCCATCCTG GGTCAGTGTCTGGTCATTTC TCAGAGCTTTGAACAGG CT
Casp9, NM_001229 AGACCAGAGATTCGCAAAC TTCCTGGAACGGGGTGGCAT AGGATTTGGTGATGTCG AT
Hells, AB102716 AAAAGGCTCGCATGTCTTGG ACTGGCTTCTCTTCACTTGC TGGAACAGCAACAATTAGAG AT
Keratin 8, NM_002273 TGAACAAGGTAGAGCTGGAG GCTGAGAGCATGTACCAGAT GTCCCAGATCTCGGACA CT
NME1, NM_000269 GCAAGACAGGTTCACAATGG CAAGCTTCCGAAGATCTTCT AACCTAAGCAGCTGGAAGG AGT
PCBP4, NM_020418 CTCACAGGAGTTCTTGGTTC CATTAGCTGCTGCCATCTTG CCAGTACCTCATCACTGCCTG CT
PPP1R11, NM_170781 GAGACCGTCACTGAGACAAC AAAGGCCCGAGGTTTCTCAT CCGTGACAACCGAGCCCGA ACG
RAB1A, NM_004160 ACAGAAAGCTACATCAGCAC GACGATGGCAGCTGAGATTA GAAAACAATCAAGCTTCAAATA ACT
REST, AF228045 GAACTCATACAGGAGAACGC GCAAGACAGGTTCACAATGG ACATATGCGTACTCATTCAG CT
TERT
Alpha NM_198255 CGCCTGAGCTGTACTTTGTC TGAGGTGAGGTGTCACCAAC GACCTCCGTGAGCCTGTCCT CG
Beta NM_196235 CGCCTGAGCTGTACTTTGTC TGAGGTGAGGTGTCACCAAC CCTTCAAGAGCCACGTC CG
VEGF, NM_003376
Set one AAACCCTGAGGGAGGCTCCT TGCTGTCTAATGCCCTGGAG GCCTCGGCTTGTCACAT CG
Set two CGAGTCTGTGTTTTTGCAGG GGCAAAAACGAAAGCGCAAG GAGCAAGGCCCACAGGGA AGT
Accession numbers are for the longest splice variant mRNA, except TERT where the accession numbers are for the specific isoforms.
aSequences for cDNA obtained from BLAT database (http://genome.ucsc.edu/).
bExample termination mixture CT indicates dATP, ddCTP, dGTP and ddTTP.
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data quality was controlled by discarding data with a fre-
quency error (a weighted uncertainty of the frequencies for
each variant reported by the SpectroTYPER software)
>10.0%. Level of quantiﬁcation (LOQ) for the MALDI-
TOF platform has been previously reported using pooled
DNA as 5.0% (18). Although some of the assays investigated
here demonstrated reproducible data at lower frequencies, the
conservative value of 5.0% was used as the LOQ. Although
this method can detect ASVs <5%, the detection is not quant-
itative at this stage. A peak was considered detected if it had a
signal-to-noise ratio >10. After the data were ﬁltered for qual-
ity, the mean and standard deviation for each splice variant
was calculated as the ﬁnal reported value.
ACTN-4 analysis
The ACTN-4 PCR product and the 1:20 dilution samples were
analyzed using a 10% TBE non-denaturing pre-cast acrylam-
ide gel (Invitrogen) using 0.5· TBE buffer. The ACTN-4 PCR
product was produced by using the PCR ampliﬁcation step
outlined in the previous assay using 100 ng of tissue cDNA
sample in a total reaction of 20 ml. The 1:20 samples were
obtained by adding 1 ml of the ACTN-4 PCR product to a total
PCR volume of 20 ml followed by a single PCR cycle. Bands
were electro-eluted using GeBA ﬂex-tubes according to
instructions, and the sequence of each band was performed
by Davis Sequencing (Davis, CA) using the same forward and
reverse primers used in the PCR.
RESULTS
To evaluate the potential use of the primer extension method
for the detection and quantiﬁcation of ASVs, examples were
selected consisting of genes whose variants are well charac-
terized and have been shown to be potential cancer markers
(BCL2L1, TERT, VEGF, HNRPA2B1 and CEACAM), a few
less-characterizedASVs, (ACTN-4,KRT8, PCBP4, Caspase 9
and HELLS) as well as some ASVs identiﬁed by data mining
techniques (REST, RAB1A, PPP1R11 and NME1). Although
there are many types of ASVs, they all share the fact that a
sequencedifference isintroduced into the mRNA.Itisthis fact
that allowed for the detection and quantiﬁcation of the splicing
events, regardless of the exact nature of the ASV. Throughout
this paper, the term ‘alternatively spliced variant’ will refer
to the cancer-associated variant and ‘normal’ will refer to non-
cancer-associated variant. Furthermore, because this analysis
uses relative percents the sum of the ASV and normal variant
is 100%, thus a 10.4% ASV has 89.6% normal variant present.
For sequence insertions (Figure 1a, c and d), the variant
sequence differs from the native sequence only in the novel
insertion whether it is a unique series of exons (REST), a
30 addition, (TERT alpha variant) or a 50 addition (BCL2L1-L).
For sequence deletions (Figure 1b), the ASV is detected in the
sequence disparity of the exon adjacent to the ﬁxed exon.
Normal splicing for TERT results in extension from exon 6
into exon7while the beta variant resultsin extension into exon
9. For mutually exclusive exons (Figure 1e), as in ACTN-4,
the extension primer is designed for the sequence portion of
the 80 exon that is unique from exon 8. Complex splicing,
such as vascular endothelial growth factor (VEGF), where
multiple splicing events can result in many variants, exten-
sion strategies are less straightforward and will be discussed
in detail later on.
The different sequences that are produced from the exten-
sion primer of each variant were detected as a speciﬁc peak in
the mass spectra. For example, in BCL2L1-L (also known as
BCL-XL), a CT dideoxy termination mixture (dATP, ddCTP,
dGTP and ddTTP) and an extension primer create a speciﬁc
concatenation of the primer, TCAGAGCTTTGAACAGG
(5234.4 m/z) plus a terminal ddT (5522.6 m/z), while the
BCL2L1-S variant (also known as BCL-xS) extends an
AddT on to the extension primer (5835.8 m/z). The
BCL2L1-L and BCL2L1-S variants are uniquely identiﬁed
by mass/charge ratios and were detected and quantiﬁed.
Detection of ASVs
To test the ability of this method to detect splice variants in 13
selected genes (Table 2), total RNA samples from six different
healthy tissues were obtained from Clontech and reverse tran-
scribed into cDNA samples. The resultant cDNAs were PCR
ampliﬁed using forward and reverse primers that were
designed to ﬂank the ASV of interest. After ampliﬁcation,
excess dNTPs were removed using SAP, a crucial step that
allows the termination mixture used in the extension cycle to
have the desired dideoxynucleotide termination sequence. In
the primer extension reaction, a primer was designed that was
complementary to the sequence directly adjacent to the
sequence difference introduced by an ASV. In the extension
cycle, ThermoSequenase was used to add the dNTPs until a
termination base was added to create a unique extension
sequence. Each sample was assayed in replicates of four with
each replicate sampled ﬁve times by the mass spectrometer.
The brain had the largest relative percent of ASVs
expressed, with 48.4%, followed by testis and heart at 35.5
and 35.7%, respectively. We should caution the readers that
our data are mainly a proof of principle to demonstrate the
methodology rather than to answer the biological question of
alternative splicing in a tissue-speciﬁc manner. The general
trend of the data in Table 2, however, does correlate with
previous EST and tissue-speciﬁc alternative splicing studies
(13,16), in which brain was found to have the highest level of
alternative splicing followed by the testis and heart.
In three of the genes that were assayed, TERT, BCL2L1 and
RAB1A, the dominant variant in at least two tissues was the
alternatively spliced variant. The most dominantly expressed
variant was the beta variant of TERT. TERT is a telomerase
reverse transcriptase that is primarily regulated transcription-
ally (19), but has also been shown to be regulated through
alterative splicing of transcripts (20) and is generally inactive
in adult tissues with the exception of male germ cells (21).
Only the full-length variant is active as both the alpha and beta
variants disrupt the required RT motifs (22). Currently, this
assay is unable to identify if both the alpha and beta deletion
occur on the same transcript; however, we can extrapolate the
presence of normal full-length variant by looking at the values
from both assays together. In the heart, 87.5% of the TERT
transcript has the beta deletion and no TERT transcripts with
the alpha deletion were detected, as a result the remaining
12.5% of the TERT transcript has neither the beta nor the
alpha deletions, leaving the possibility that those transcripts
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testis tissue contained the beta deletion and 19.9% of those
transcripts possessed the alpha deletion, indicating that both
the alpha and beta deletion were present on  15–20% of the
TERT mRNAexpressed inthe testis. Withthe exception of the
heart, no full-length TERT transcripts were detected in any of
the tissues.
BCL2L1-L, a well-known anti-apoptic variant in the Bcl-2
family of cell death regulators, has been linked to a variety of
cancers, including lung (23), myeloma (24), brain (25) and
breast (26). In most studies, the up-regulation or down-
regulation of the BCL2L1-L variant, rather than BCL2L1-S,
is monitored. For those studies that do monitor both variants,
the values are represented as a ratio of the two variants.
Given how well studied this variant is, it is surprising that
an alternative splice variant proﬁle in normal tissues has not
been presented in previous studies; however, it is clear that the
BCL2L1-L is the dominant variant in murine tissue (27). Our
data show that of the two variants, BCL2L1-L and BCL2L1-S,
BCL2L1-L is close to or above 50% in all samples with the
highest percent in the heart with 69.8%.
RAB1A, a member of the RAS oncogene family, ASV
tissue proﬁle has not been studied outside of EST computa-
tional analysis (28), but ourdata demonstrate that thisalternate
variant expressed at near 50% in all tissues with a high of
56.6% in the brain and a low of 40.0% in the testis.
In contrast to the ASVs that were predominantly expressed,
four of the genes show either minor ASV expression in all
(a)
(b)
(c)
(d)
(e)
Figure 1. Alternativesplicingisoformanalysisviaprimerextension.Allclassificationsofsplicingcanbeanalyzedincludingexoninsertion(a),exondeletion(b),30
splicingacceptor(c),50 splicingdonor(d)andmutuallyexclusiveexons(e).Exonlengthsarenottoscale.Primerextensionassaysofrespectivegeneswereassayed
on a MALDI-TOF MS. In the mass spectra, extension primer refers to unextended primers, while the subsequent peaks indicate the primer with an extension of the
base(s) specified.
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four ASVs, three, Keratin 8, NME1 and PCBP4, have only
been recently identiﬁed and lack a prior tissue-speciﬁc distri-
bution proﬁle. Keratin 8, recently discovered in non-small cell
lung cancer (29), had an average ASV expression level of
7.1% and was consistently detected in all samples, with the
exception of the brain, which expressed the full-length KRT8
exclusively. NME1 (non-metastatic cells 1) ASV was identi-
ﬁedintwoESTscreeningpapers,indicatingitspotentialuseas
a cancer marker (28,30). This variant was not detected in any
normal tissues. PCBP4, a poly(rC)-binding protein gene, ASV
was detected in all tissues with the highest expression in the
brain and heart samples at 39.2 and 36.2%, respectively, the
remaining samples had expression levels between 21.8 and
10.6%.Recently,conversionofPCBP4tothisdeletionvariant,
PCBP4a, has been correlated with lung cancer (31). The fourth
minor ASV, REST, a RE1-silencing transcription factor, was
expressed exclusively in the testis at 6.8%. Previously, this
ASV had been detected in lung cancer cell lines expressed at
similar levels as the wild-type variant as well as in brain at
such low abundance that it was only detected after using
nested PCR (32).
The ﬁnal gene analyzed was ACTN-4, in which the altern-
atively spliced 80 exon was detected in all tissue samples with
two samples showing a >50% expression, the testis and brain,
at 51.2 and 71.1%, respectively. This variant, similar to those
with low-level expression, has only recently been identiﬁed in
lung cancer cell lines, where the ASV containing the 80 exon
was onlydetectedinsmall celllungcancer, with trace amounts
in testis and the brain (33). Since this ASV was detected in all
tissue samples we tested, in contrast to the previously reported
expression proﬁle data, additional analysis was performed to
conﬁrm the expression level of the 80 exon in ACTN-4.
Paired extension primer correlation
To conﬁrm the expression levels of the 80 exon, ACTN-4 was
assayed using two extension primers, one coming from the 50
side of exon 80, as originally used, and one from as the 30 side
(Figure 2). Both primers were designed adjacent to unique
bases in the 80 exon. The samples were multiplexed, a process
that allows the two extension primers to be assayed simultan-
eously in the same reaction reducing procedural variations and
increasing throughput. The extension primers of the multi-
plexed assays were designed with a different termination
mixture so that the mass spectra for both the forward and
reverse product of each variant would not interfere with
each other. When both forward and reverse extension product
values of the 80 ACTN-4 exon were compared with each other
(Figure 3) both values correlated well. With the values veriﬁed
using bidirectional analysis, we suspected that the disparity of
our results with previously published data was a result of the
formation of heteroduplexes during PCR.
ACTN-4 exon 80 heteroduplex analysis
The mutually exclusive splice variant of ACTN-4 is inherently
difﬁcult to assay via conventional PCR and gel analysis tech-
niques. ASVs are generally analyzed by comparing the migra-
tion of the variants, which is the result of their molecular
weight difference by either a deletion or insertion. For
ACTN-4, the mutually exclusive exon is 83 nt,the same length
as the constitutive exon 8 precluding it from this type of
analysis. Using a restriction enzyme that digests one variant
but not the other can create a difference in migration between
the two variants, as was performed with ACTN-4 (33). Con-
founding problems of this adaptation include heteroduplexes.
When two sequences have a high percent of homology, they
are prone to form heteroduplexes during PCR. Heteroduplexes
are not digested fully as only one strand of the DNA has the
correct restriction site. Exons 8 and 80 are 74.4% identical,
while the entire amplicon between the forward and reverse
primer (223 nt) has only 21 different residues resulting in a
>90% identity.
To determine whether heteroduplexes were formed during
conventional analysis, the PCR product using the same PCR
primers as the mass extend assay was assayed on a non-
denaturing 10% polyacrylamide gel. This type of heteroduplex
Table 2. Relative splice variant expression profile in six tissue samples
Gene Variant (description) Percent of described splice variant (standard deviation)
Brain Colon Heart Kidney Liver Testis
HNRP A2B1 B1 (insertion of 36 nt in B1 between exons 1 and 2) 7.1 (1.0) 6.7 (1.4) 6.8 (1.0) 8.2 (1.1) 8.6 (1.9) 6.9 (3.1)
ACTN-4 (Alternative exon 80 replaces existing exon 8) 71.1 (4.0) 25.7 (2.3) 16.9 (5.2) 32.7 (5.1) 11.9 (3.8) 51.2 (3.8)
BCL2L1 BCL2L1-L (insertion of 189 nt on the 50 end of exon 2) 61.0 (13.9) 56.0 (9.7) 69.8 (9.8) 65.6 (11.5) 49.1 (11.4) 49.0 (9.7)
CASP9 Caspase 9b (deletion of 450 nt, including exons 3–6) 8.9 (7.2) <5.0 10.2 (7.2) 8.4 (6.7) 9.4 (7.4) <5.0
Hells (Insertion of 44 nt between exons 3 and 4) <5.0 13.9 (5.3) <5.0 <5.0 <5.0 <5.0
Keratin 8 (Deletion of 44 nt within exon 5) ND 7.8 (1.0) 5.3 (0.6) 7.6 (0.4) 7.7 (0.7) <5.0
NME1 (Insertion of 220 nt between exons 1 and 2) ND ND ND ND ND ND
PCBP4 PCBP4a (deletion of 197 nt from the 30 end of exon 13) 39.2 (11.4) 21.8 (8.9) 36.2 (10.3) 10.6 (3.8) 13.0 (5.7) 14.9 (6.0)
PPP1R11 (Insertion of 75 nt between exons 1 and 2) ND ND ND ND ND <5.0
RAB1A (Deletion of 228 nt, including exons 4 and 5) 56.6 (4.7) 45.7 (2.9) 52.5 (4.3) 48.4 (4.0) 50.4 (3.0) 40.0 (2.3)
REST (Insertion of 50 nt between exons 5 and 6) ND ND ND ND ND 6.8 (1.0)
TERT Alpha (deletion of 36 nt at the 50 end of exon 6) <5.0 <5.0 ND ND ND 19.9 (10.0)
VEGF VEGF121 (deletion of 273 nt, including exons 6 and 7) 41.1 (4.7) 73.5 (7.1) 36.6 (7.4) 49.0 (5.1) 61.3 (8.3) 75.2 (8.9)
VEGF206 (inclusion of exons 5 through 8) ND ND ND ND ND <5.0
Average 48.4 34.1 35.7 35.2 31.3 35.5
The values are for the variant described to the right of each gene. Relative percent expression of each variant was obtained from four separate reverse transcription
reactionswitheachreversetranscriptionreactionPCRamplifiedinreplicatesoffour(n = 16).Thestandarddeviationbetweenthereplicatesisinparentheses.Values
abovethelevelofdetection butbelowthe LOQof5.0%,areindicatedas<5.0.Values>95.0%weremarkedwith>95.0,exceptwhereonlyonevariantwasdetected
in which case the ASV is 100.0%. Variants not detected are marked ND. Averages for overall tissue splicing do not include VEGF data.
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thatwouldordinarilyappearasasinglebandonanagarosegel,
as was seen for these samples (data not shown). HMA on two
samples in lanes 4 and 5 produced three bands of different
migration with one major band, 3, and two minor bands, 1 and
2 (Figure 4a). To determine whether these additional bands
wereheteroduplexes, aliquots of the samples run inlanes 4and
5 were diluted 1:20 and subjected to a single PCR cycle, a
process that allows heteroduplexes to denature so that correct
duplexes can be re-established (35). As expected, the two-
heteroduplex bands were absent in lanes 2 and 3. Finally,
to conﬁrm the heteroduplex analysis results and to ascertain
the exact duplexes formed, the three bands from lanes 4 and
5were extracted fromtheacrylamideandsequencedfromboth
directions. The sequencing results conﬁrmed that bands 1 and
2 were heteroduplexes formed by exon 80 forward/8 reverse
andexon8forward/80 reverse,respectively(Figure4b).Band3
was a homoduplex of both exon 8 forward/8 reverse. Band
3 may also contain a homoduplex of exon 80 forward/80 reverse
at a much smaller amount compared with exon 8 forward/
8 reverse so that it is not directly detectable by sequencing.
VEGF variant analysis
After demonstrating the ability of this method to detect simple
slice variants, we then moved to a more complex example,
VEGF, a gene that plays a crucial role in angiogenesis, the
formation of new capillaries (36). With such a vital role in
vascularization and its correlation to cell proliferation, VEGF
has long been considered an important factor in tumorigenesis
witharoleineverymajor typeofcancer (37)andthusanatural
target for therapy. VEGF has six splice variants (Figure 5a)
ranging from 121 to 206 amino acids. Because of the com-
plexity of the splicing, a single extension primer is not sufﬁ-
cient to identify all variants; as a result two extension primers
were used, each one giving a portion of the data that together
would give the relative abundance of each variant to all the
variants(Figure5b).Extension primer1was usedtodetermine
the relative expression of 121 and 145 relative to the sum of
VEGF 165, 183, 189 and 206. The second extension primer
was designed to detect only the variants not distinguished in
the ﬁrst extension reaction (165, 183, 189 and 206). This
allowed us to take the individual results for VEGF 165,
183, 189 and 206 and back calculate the percent of each
variant relative to all the variants (Figure 5c).
Thedataobtainedfromthe twoextensionprimerscorrelated
with previous tissue proﬁle data, with 121 and 165 represent-
ing the bulk of the variants in all tissues (38). Historically, as
the minor variants were being revealed, two variants, 183 and
189,wereinitiallynotdifferentiated becauseoftheirsmallsize
difference, 18 nt. Lei et al. (39) had suggested that previously
identiﬁed 189 in the heart was probably 183. Both of the
variants 183 and 189 were identiﬁed to be most highly
expressed in the heart at 11.2 and 8.6%, respectively, clarify-
ing that both 183 and 189 are present in the heart. The remain-
ing variants, 145 and 206, are rarely expressed and ostensibly
limited to placental cells (40); however, there was a detectable
level of 206 in testis.
DISCUSSION
We have shown that primer extension coupled with MALDI-
TOF MS can be applied to high-throughput ASV detection and
quantiﬁcation.The tissue proﬁles demonstratedby thismethod
are not meant to be deﬁnitive values, rather an illustration of
the power of this method to generate statistically signiﬁcant
Figure2.ForwardandreverseextensionprimersforACTN-4variants.Extensionprimer1onthe50 sideofthemutuallyexclusiveexonistheforwardprimerwithCA
indicatingtheextendedbasesforexon8andTindicatingtheextendedbaseforexon80.Extensionprimer2onthe30 sideofthemutuallyexclusiveexonisthereverse
primerwithCGindicatingtheextendedbasesforexon8andAindicatingtheextendedbaseforexon80.Allreactionsweremultiplexedinthesamewellandassayed
together. An AGT termination mixture (ddATP, dCTP, ddGTP and ddTTP) was used for the primer extension reaction.
Bidirectional Actinin Exon 8' Variant Analysis
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
Brain Colon Heart Kidney Liver Testis
R
e
l
a
t
i
v
e
 
E
x
p
r
e
s
s
i
o
n
Forward Reverse
Figure 3. Bidirectional ACTN-4 exon 80 variant analysis. Values for the
forward and reverse primers were obtained from the 50 extension primer and
the 30 extension primer, respectively. Error bars show the standard deviation.
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(VEGF). Furthermore, this method can be used to quantify
ASVs with similar length and sequence that may be erro-
neously assayed by traditional RT–PCR gel electrophoresis
method (ACTN-4). The promise of this method, coupled
with theversatilityofthe MALDI-TOFMS platform,indicates
a potential for information-rich analysis for a multitude of
uses. Use of this method, however, is limited to those
(a) (b)
Figure 4. Heteroduplex mobility analysis and sequencing of ACTN-4. (a) 10% TBE non-denaturing acrylamide gel analysis. Lane 1, 100 bp marker; lane 2, 1:20
dilution of lane 4 sample with 1 cycle of PCR; lane 3, 1:20 dilution of lane 5 sample with 1 cycle of PCR; lanes 4 and 5, undiluted PCR amplification product using
ACTN-4primersfromTable1.Lanes2and3haveonebandat223nt(band3);lanes4and5havethesamebandat223ntandtwoadditionalbandswithlessmobility,
bands 1 and 2. These bands were extracted from the acrylamide gel using electro-elution and sequenced using the forward and reverse primers used in the PCR
amplification. (b) Sequencing analysis shows the unique sequences to exon 8 in green and exon 80 in red.
(a)
(b)
(c)
Figure 5. VEGF exon map. (a) Different ASVs. (b) Two extension primers designed to distinguish all six ASVs. Primer one targeting the 50 end of exon eight was
usedtodistinguishVEGF121,VEGF145andthesumofVEGF165,VEGF183,VEGF189andVEGF206.Primertwotargetingthe50 endofexonsevenwasusedto
distinguishVEGF165,VEGF183,VEGF189andVEGF206(primer2doesnotdetectVEGF121andVEGF14).(c)CalculationofeachVEGFASVs.Datausedinthis
figure are for illustration only and do not reflect data from any sample assayed.
PAGE 7 OF 9 Nucleic Acids Research, 2005, Vol. 33, No. 11 e99ASVs that have been characterized at the sequence level
and is currently not able to identify new variants. Thus, this
method can function as a complement to the enormous
dataset generated from cDNA sequencing and computational
analyses.
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